An Observational Study of the Efficacy and Safety of Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma
This is a multicenter real world study (RWS) initiated by the investigator. Eligible patients will be selected for treatment with second-line treatment including vorolanib and followed up. The real survival data of patients after medication will be collected and compared with the data of CONCEPT study, and multi-factor stratified analysis of the efficacy of voronib will be conducted.
• Subjects have fully understood and voluntarily signed the informed consent form (ICF);
• 18-80 years old (at the time of signing the informed consent); Both men and women; ECOG PS score: 0-1;
• Renal cell carcinoma with clear cell components confirmed histologically or cytopathologically, including unresectable or recurrent metastatic renal cell carcinoma dominated by clear cell components;
• According to RECIST (version 1.1), there are targets that are considered to be observable;
• The main organs function well.